Author

Rachel N. Ruggerie

Institution: Cartesian Therapeutics, Inc. (United States)

Observed institution: Cartesian Therapeutics, Inc. (United States)

ORCID: 0009-0008-2578-3028

Observed ORCID: 0009-0008-2578-3028

OpenAlex ID: A5122336239

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

2026 · Tuan Vu, Hacer Durmus, et al. · Nature Medicine · 38

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

2026 · Renee R. Fedak, Rachel N. Ruggerie, et al. · Nature Medicine · 26

Works count: 2

Citation count: 64

H-index: 2

I10-index: 2